 Since 2008, at least 30 prodrugs have been approved by the FDA.Seven prodrugs were approved in 2015 and six in 2017.Examples of recently approved prodrugs are such as dabigatran etexilate (approved in 2010), gabapentin enacarbil (2011), sofosbuvir (2013), tedizolid phosphate (2014), isavuconazonium (2015), aripiprazole lauroxil (2015), selexipag (2015), latanoprostene bunod (2017), and benzhydrocodone (2018).